Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Gilead Sciences (NASDAQ:GILD) had its target price increased by equities researchers at Royal Bank Of Canada from $103.00 to $118.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential downside of 24.22% from the stock’s current price.

Other analysts also recently issued reports about the company. Needham & Company LLC upped their price objective on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday. Citigroup increased their price target on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. UBS Group boosted their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Twenty-five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.04.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded up $8.48 during trading on Wednesday, reaching $155.71. The company’s stock had a trading volume of 5,072,874 shares, compared to its average volume of 7,745,895. The company has a 50-day moving average price of $128.39 and a two-hundred day moving average price of $121.53. Gilead Sciences has a fifty-two week low of $93.37 and a fifty-two week high of $156.88. The firm has a market cap of $193.19 billion, a PE ratio of 24.21, a P/E/G ratio of 0.80 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same period in the previous year, the business posted $1.90 earnings per share. Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the sale, the insider directly owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 319,391 shares of company stock valued at $44,141,101 over the last ninety days. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in GILD. Syon Capital LLC grew its position in Gilead Sciences by 5.0% in the fourth quarter. Syon Capital LLC now owns 21,277 shares of the biopharmaceutical company’s stock worth $2,612,000 after buying an additional 1,008 shares during the last quarter. ING Groep NV grew its holdings in shares of Gilead Sciences by 95.1% during the fourth quarter. ING Groep NV now owns 364,354 shares of the biopharmaceutical company’s stock valued at $44,721,000 after buying an additional 177,642 shares in the last quarter. Vermillion Wealth Management Inc. lifted its stake in Gilead Sciences by 623.0% in the 4th quarter. Vermillion Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock worth $89,000 after acquiring an additional 623 shares in the last quarter. Valtrion Capital Management LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $300,000. Finally, DB&C Advisors LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $1,569,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat — Gilead topped top‑ and bottom‑line estimates, driven by strong HIV and liver disease drug sales and early momentum for new product Yeztugo. Analysts highlighted margin strength as well. GILD’s Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms raised PTs and maintained overweight/buy ratings (Morgan Stanley to $171, Needham to $170, Wells Fargo to $165, JPMorgan to $160, Scotiabank to $177), bolstering demand and helping push the stock higher. Morgan Stanley raises price target to $171 Needham maintains Buy, raises PT to $170
• Positive Sentiment: Dividend increase — Board raised the quarterly dividend to $0.82 (3.8% increase), supporting income‑oriented investor interest. Gilead Sciences Announces 3.8-Percent Increase in First Quarter 2026 Dividend
• Neutral Sentiment: Earnings call and materials available — Full Q4 call transcript and slide deck provide detail on product trends, pipeline timing (including potential cancer therapy submissions) for investors doing deeper due diligence. Gilead Q4 2025 Earnings Call Transcript
• Negative Sentiment: Conservative FY2026 guidance — Management set FY26 EPS and revenue guidance at the low end (EPS 8.45–8.85; revenue ~ $29.6–30.0B), below consensus in some estimates, which prompted after‑hours weakness and caution among some investors. Gilead 2026 outlook short of Wall Street view, shares dip Reuters: Gilead quarterly results beat Wall Street estimates

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.